In a mouse model of amyotrophic lateral sclerosis, animals that had ample levels the bacterium Akkermansia muciniphila in their gut microbiomes fared better than those carrying almost no members of the species, which produces vitamin B3, according to a study published this week (July 22) in Nature. Moreover, restoring A. muciniphila in mice that had low levels slowed the progression of their disease.
“When we gave it to ALS-prone mice it very significantly improved ALS severity in these mice,” coauthor Eran Elinav, a microbiome researcher at the Weizmann Institute of Science in Israel and of the German Cancer Research Center in Heidelberg, tells The Guardian. On the other hand, two other members of the microbiome—Ruminococcus torques and Parabacteroides distasonis—were more common in mice with severe disease.
The researchers suspect that A. muciniphila’s production of B3 may have something to...
The researchers gathered some preliminary data that suggest A. muciniphila abundance may relate to ALS in humans as well. Examining the microbiomes of 37 ALS patients and 29 healthy family members, Elinav and colleagues found lower levels of the bacterium in the stool of the ALS patients and lower levels of nicotinamide in their blood and cerebrospinal fluid. In addition, the levels of nicotinamide in the blood correlated with the severity of the patient’s disease: patients with lower levels tended to have worse symptoms.
“We have to prove that what we found in mice is reproducibly found in humans,” Elinav tells Science News.
Jef Akst is the managing editor at The Scientist. Email her at firstname.lastname@example.org.